System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Claus Garbe, MD is an expert in Oncology at Universitätsklinikum Tübingen (Germany). As of October 2026, ScienceLeadR ranks Claus Garbe in the top 1% of experts worldwide for Skin Neoplasms and Melanoma. Claus Garbe has authored 1,000 publications, the most recent in 2026, and is an investigator in 44 clinical trials. SLR score: 3,523 (community average: 125). How the SLR is computed.

LeadR Profile

Claus Garbe, MD Universitätsklinikum Tübingen Germany
3 523 ScienceLeadR Reputation 3523

Unlock

Register Login
Network Map

Oncology

Subspecialties: Dermatology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1989 - 2026
Source: PubMed

University of Tübingen

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1000

Citations

Citations: 78 526 1st author: 91 Last author: 241 Unique author: 34

Main journals

J Clin Oncol 90
Eur J Cancer 86
J Dtsch Dermatol Ges 82
Hautarzt 57
Melanoma Res 45

Best Journals

Lancet Oncol 16
Ann Oncol 15
J Clin Oncol 14

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Improvement of overall survival in patients with cutaneous melanoma at a tertiary care center in Germany from 2001 to 2020.
PMID 42703903 — tertiary care centers, melanoma, skin diseases, immune checkpoint inhibitors, therapeutics, tertiary healthcare		J Dtsch Dermatol Ges20260
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.
PMID 42393046 — registries, biological science disciplines, probability, melanoma, neoplasms, diagnosis, prospective studies		Nat Commun20261
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment - update 2026.
PMID 42263355 — radiotherapy, cells, carcinoma, squamous cell, neoplasms, therapeutics, cutaneous squamous cell carcinoma		Eur J Cancer20260
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026.
PMID 42248744 — cells, carcinoma, squamous cell, neoplasms, neoplasm metastasis, risk factors, cutaneous squamous cell carcinoma		Eur J Cancer20260
Genetic landscape of stage II melanoma identifies CBL as a new driver gene and prognostic biomarker.
PMID 41957139 — genes, melanoma, neoplasms, biomarkers, therapeutics, mutation		Br J Cancer20260

Clinical Studies 44

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 18 Study Director: 1

By phase:

Phase 3 19
Phase 2 13
Phase 1/Phase 2 5
N/A 4
Phase 4 3

By status:

Completed 30
Unknown 6
Terminated 5
Recruiting 2
Active not recruiting 1

By type:

Interventional 42
Observational 2

By Monocentric/Multicentric:

monocentric 10
multicentric2to4 5
multicentric5to9 1
multicentricup10 28

Main Topics

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS